

O'Brien MP, Forleo-Neto E, Sarkar N, et al; COVID-19 Phase 3 Prevention Trial Team. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial. *JAMA*. Published online January 14, 2022. doi:10.1001/jama.2021.24939

## Data Sharing Statement

### Data

**Data available:** Yes

**Data types:** Other (please specify)

**Additional Information:** Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to <https://vivli.org/>.

**How to access data:** Submit requests to <https://vivli.org/>.

**When available:** With publication

### Supporting Documents

**Document types:** None

### Additional Information

**Who can access the data:** Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to <https://vivli.org/>.

**Types of analyses:** Submit requests to <https://vivli.org/>.

**Mechanisms of data availability:** Submit requests to <https://vivli.org/>.